The journey of CAR-T therapy in hematological malignancies
Authors:
Top Cited Papers
Open Access
- 8 October 2022
- journal article
- review article
- Published by Springer Nature in Molecular Cancer
- Vol. 21 (1) , 1-15
Abstract
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products, such as Kymriah, Yescarta and Tecartus, have been developed and got the unprecedented results. However, some patients may relapse afterwards, driving intense investigations into promoting the development of novel strategies to overcome resistance and mechanisms of relapse. Notable technical progress, such as nanobodies and CRISPR-Case9, has also taken place to ensure CAR-T cell therapy fully satisfies its medical potential. In this review, we outline the basic principles for the development and manufacturing processes of CAR-T cell therapy, summarize the similarities and differences in efficacy of different products as well as their corresponding clinical results, and discuss CAR-T immunotherapy combined with other clinical effects of drug therapy.Keywords
This publication has 136 references indexed in Scilit:
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesPLOS ONE, 2011
- The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 ComplexThe Journal of Immunology, 2010
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22Blood, 2010
- IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune responseBlood, 2008
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow CytometryImmunological Investigations, 2006
- T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cellsGene Therapy, 2003
- Targeting tumours with genetically enhanced T lymphocytesNature Reviews Cancer, 2003